T-DXd: Clinical Trials

28 trials of T-DXd, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

16 recruiting, 6 not yet recruiting, 4 active not recruiting, 2 completed. 28 Phase 2, 10 Phase 1.

By phase and status

PhaseTrialsStatus
Phase 228Recruiting 16, Not yet recruiting 6, Active not recruiting 4, Completed 2
Phase 110Recruiting 8, Completed 1, Not yet recruiting 1

Follow T-DXd: new trials by email Literature Review of T-DXd trials Research Report on T-DXd

Trials (filtered) newest first · largest first

All 28 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Testing the Combination of Anti-Cancer Drugs, Selumetinib and DS-8201a (Trastuzumab Deruxtecan), for Advanced Pancreatic Ductal Adenocarcinoma
Biospecimen Collection, Diagnostic Imaging Testing, Echocardiography Test - Advanced Pancreatic Ductal Adenocarcinoma, Metastatic Pancreatic Ductal Adenocarcinoma
Phase 1 / Phase 2RecruitingNational Cancer Institute (NCI)312027-06-012026-10-22
Study of Trastuzumab Deruxtecan (T-DXd) in Combination With a RAGE Inhibitor in Patients With T-DXd-Resistant HER2-Positive or HER2-Low Metastatic Breast Cancer
Azeliragon, T-DXd - T-dxd Resistant HER2-Positive, HER2 Low Metastatic Breast Cancer
Phase 1 / Phase 2Not yet recruitingThe Methodist Hospital Research Institute272026-12-012026-08-25
Trastuzumab Deruxtecan and Lovastatin in HER2-low and Ultralow Advanced or Metastatic Breast Cancer
Trastuzumab deruxtecan, Lovastatin - Breast Cancer, Advanced Breast Cancer
Phase 2Not yet recruitingWashington University School of Medicine602026-11-302026-11-02
A Study of Trastuzumab Deruxtecan (T-DXd) and Cetuximab in People With Colorectal Cancer
Fam-Trastuzumab Deruxtecan-Nxki - Colorectal Cancer, Adenocarcinoma of the Colon
Phase 2Not yet recruitingMemorial Sloan Kettering Cancer Center272026-10-012026-10-01
A Study of Patritumab Deruxtecan (HER3-DXd) in Combination With Trastuzumab Deruxtecan (T-DXd) in Participants With HR-Positive, HER2-Low or HER2-Ultralow Unresectable or Metastatic Breast Cancer
Patritumab deruxtecan, Trastuzumab deruxtecan - Hormone Receptor Positive, HER2-low or HER2-ultralow
Phase 1 / Phase 2RecruitingDaiichi Sankyo2202026-09-172026-10-01
Sotorasib in Combination With Trastuzumab Deruxtecan for the Treatment of Locally Advanced and Metastatic Non-small Cell Lung Cancer With a KRAS G12C Mutation
Biopsy Procedure, Biospecimen Collection, Computed Tomography - Locally Advanced Lung Non-Small Cell Carcinoma, Metastatic Lung Non-Small Cell Carcinoma
Phase 1 / Phase 2RecruitingNational Cancer Institute (NCI)372026-06-172026-09-04
Efficacy and Safety of Trastuzumab Rezetecan or Trastuzumab Deruxtecan in Advanced Breast Cancer
Trastuzumab Rezetecan for Injection (SHR-A1811), Trastuzumab Deruxtecan for Injection (T-DXd) - Advanced Breast Cancer
Phase 2Not yet recruitingSun Yat-Sen Memorial Hospital of Sun Yat-Sen University1002026-06-012026-06-05
SHR-A1811 vs Pyrotinib/Capecitabine in Trastuzumab-Resistant HER2+ Advanced Breast Cancer: A Randomized Study
SHR-A1811, Pyrotinib, Capecitabine - Breast Cancer, HER2-positive Breast Cancer
Phase 2Not yet recruitingPeking University Cancer Hospital & Institute1002026-03-312026-02-18
Trastzumab Deruxtecan Versus SOC in Recurrent Ovarian That Progressed on Prior PARP Inhibitor Therapy
Trastzumab Deruxtecan, Bevacizumab, Platinum Based Chemotherapy - Ovarian Cancer, Ovarian Carcinoma, Recurrent
Phase 2RecruitingYonsei University1162026-02-262026-04-20
Trastuzumab Deruxtecan in First-Line HER2-Positive Metastatic Breast Cancer With Proactive Toxicity Management
Digital Health Tools, T-DXd, Pertuzumab - Breast Cancer Stage IV
Phase 2RecruitingSOLTI Breast Cancer Research Group3002026-02-182026-03-27
ERADICATE: A Phase Ib/II Study of Elacestrant Plus Trastuzumab Deruxtecan in Patients With CDK4/6 Inhibitor and Endocrine-resistant HR+/HER2-low or HER2-ultralow Metastatic Breast Cancer
Elacestrant, Trastuzumab Deruxtecan - Metastatic Breast Cancer, HER2 Low Breast Carcinoma
Phase 1 / Phase 2RecruitingKristina A. Fanucci652025-11-172026-06-10
Phase I/II Study of Intrathecal/Ommaya T-DXd in HER2-Expressing Breast Cancer With Leptomeningeal/Brain Metastases
T-DXd - Breast Cancer
Phase 1 / Phase 2RecruitingFudan University1392025-05-122026-10-26
Personalized Antibody-Drug Conjugate Therapy Based on RNA and Protein Testing for the Treatment of Advanced or Metastatic Solid Tumors (The ADC MATCH Screening and Treatment Trial)
Biopsy Procedure, Biospecimen Collection, Computed Tomography - Advanced Malignant Solid Neoplasm, Metastatic Malignant Solid Neoplasm
Phase 2RecruitingNational Cancer Institute (NCI)5002025-03-182026-10-20
TReatment of ADC-Refractory Breast CancEr With Dato-DXd or T-DXd: TRADE DXd
Trastuzumab Deruxtecan, Datopotamab Deruxtecan - Breast Cancer, HER2-low Breast Cancer
Phase 2RecruitingAna C Garrido-Castro, MD3572024-10-292026-08-26
Trastuzumab Deruxtecan(T-DXd) and Afatinib Combination in HER2-low Advanced Gastric Cancer
Trastuzumab deruxtecan, Afatinib - Stomach Neoplasm
Phase 1 / Phase 2RecruitingJeeyun Lee612024-09-302025-12-15
T-DXd Versus THP for Medium-risk HER2-positive Early Breast Cancer
T-DXd, THP - HER2-positive Breast Cancer
Phase 2Not yet recruitingFudan University2422024-09-012024-08-12
The SAPPHO Study: Sequential Therapy With Curative Intent in de Novo HER2+ Metastatic Breast Cancer
Nab-Paclitaxel, Paclitaxel, Docetaxel - Breast Cancer Female, Breast Cancer
Phase 2RecruitingDana-Farber Cancer Institute722024-08-082026-08-06
PHESGO Maintenance After T-DXd Short Induction for HER2+ Unresectable Locally Recurrent or Metastatic Breast Cancer
Trastuzumab deruxtecan, Phesgo 1,200 MG / 600 MG / 30,000 UNT Per 15 ML Injection, Phesgo 600 MG / 600 MG / 20,000 UNT in 10 mL Injection - HER2-positive Breast Cancer
Phase 2Active not recruitingMedSIR1652024-07-222026-04-29
A Phase 1/2 Study of IAM1363 in HER2 Cancers
IAM1363, Oral treatment with IAM1363 capsules or tablets, administered in combination with capecitabine + trastuzumab, Oral treatment with IAM1363 capsules or tablets, administered in combination with capecitabine + zanidatamab - HER2 Mutation-Related Tumors, HER2
Phase 1 / Phase 2RecruitingIambic Therapeutics, Inc4632024-03-252026-11-17
A Study of T-DXd as Monotherapy or in Combination With Anti-cancer Agents in Patients With Selected HER2-expressing Tumors
Trastuzumab deruxtecan, Bevacizumab - Advanced Solid Tumors (Excluding Gastric Cancer and Breast Cancer)
Phase 2Active not recruitingAstraZeneca1272024-02-222026-09-03

Showing 20 of 28. Sign in to see all of them.

Conditions studied

Breast Neoplasms (12)  ·  Colorectal Neoplasms (4)  ·  Carcinoma, Non-Small-Cell Lung (3)  ·  Neoplasm Metastasis (3)  ·  Stomach Neoplasms (3)  ·  Brain Neoplasms (2)  ·  Colonic Neoplasms (2)  ·  Pancreatic Neoplasms (2)  ·  Rectal Neoplasms (2)  ·  Adenocarcinoma (1)  ·  Desmoplastic Small Round Cell Tumor (1)  ·  Glioblastoma (1)  ·  Lung Neoplasms (1)  ·  Meningeal Carcinomatosis (1)  ·  Neoplasm, Residual (1)

Sponsors

National Cancer Institute (NCI) (4)  ·  AstraZeneca (3)  ·  Daiichi Sankyo (2)  ·  Fudan University (2)  ·  Memorial Sloan Kettering Cancer Center (2)  ·  Ana C Garrido-Castro, MD (1)  ·  Dana-Farber Cancer Institute (1)  ·  Iambic Therapeutics, Inc (1)  ·  Jeeyun Lee (1)  ·  Kristina A. Fanucci (1)  ·  MedSIR (1)  ·  NRG Oncology (1)  ·  National Cancer Center Hospital East (1)  ·  Peking University Cancer Hospital & Institute (1)  ·  QuantumLeap Healthcare Collaborative (1)

Countries

United States (18)  ·  South Korea (7)  ·  Spain (7)  ·  France (6)  ·  Italy (5)  ·  China (4)  ·  Japan (4)  ·  Belgium (3)  ·  Germany (3)  ·  Taiwan (3)  ·  United Kingdom (3)  ·  Australia (2)  ·  Canada (2)  ·  Netherlands (2)  ·  Austria (1)

Top investigators

Alan L Ho (1)  ·  Ana Garrido-Castro, MD (1)  ·  Andreas N Saltos (1)  ·  Andrew A Davis, MD (1)  ·  Antonio Llombart-Cussac, MD (1)  ·  Damon R Reed (1)  ·  Funda Meric-Bernstam (1)  ·  Hanfang Jiang (1)  ·  Jeeyun Lee, Ph, MD (1)  ·  John Heymach, M.D, Ph.D (1)

Results publications

PMID 37870536, PMID 38351187, PMID 39116902, PMID 39261417, PMID 41213241, PMID 41487064, PMID 42131734, PMID 42135959

NIH funding

2023 (3), 2017 (1), 2025 (1), U10CA180868 (1), UM1CA186644 (1), UM1CA186688 (1), UM1CA186689 (1), UM1CA228823 (1)